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Abstract 
Background: The molecular mechanisms underlying the development and progression of gastric carcinoma remain 
poorly understood. The main objective of this study was to investigate the expression level of targeting protein for 
Xenopus kinesin-like protein 2 (TPX2) and its clinical significance in human gastric carcinoma.
Methods: Real-time quantitative polymerase chain reaction (RT-PCR) and western blotting were used to determine 
the mRNA and protein levels of TPX2 in 20 paired gastric carcinoma tissues and the adjacent normal tissues, and the 
expression of TPX2 protein in 106 specimens of a gastric carcinoma tissue microarray was determined by immuno-
histochemistry. The associations of TPX2 expression with the clinicopathological features were analyzed, and the 
prognosis of gastric carcinoma patients was evaluated.
Results: The results showed that the expression of TPX2 mRNA was significantly higher in gastric carcinoma than 
in the adjacent normal tissues in 20 paired samples. Western blotting analysis revealed that TPX2 protein was differ-
entially increased in 17 of 20 specimens from primary human gastric carcinoma tissues compared with those from 
adjacent non-tumor tissues. Immunohistochemical staining showed that TPX2 over-expression was significantly 
associated with advanced age (P = 0.001) and tumor T stage (P = 0.003). In addition, TPX2 was an independent prog-
nostic factor for overall survival (OS) in the multivariate analysis [hazard ratio (HR) 0.001; 95 % confidence interval (CI) 
2.626–7.198; P = 0.001].
Conclusions: TPX2 is up-regulated in gastric carcinoma and is associated with old age and tumor T stage. TPX2 may 
serve as a good prognostic indicator in patients with gastric carcinoma.
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Background
Among cancers, gastric carcinoma is ranked second 
worldwide as a cause of mortality [1], with 85,000 peo-
ple diagnosed with the disease each year [2] and 65,000 
people dying of the disease in China each year [3]. Gas-
tric carcinoma is not sensitive to chemotherapy and 
radiotherapy [4, 5], and its prognosis remains poor [6], 
primarily because of the lack of a specific prognostic 
index [7]. Thus, it is of great importance to identify bet-
ter biomarkers for gastric carcinoma in order to make 
a prognosis and guide therapeutic options. Targeting 
protein for Xenopus kinesin-like protein 2 (TPX2) is a 
microtubule-associated protein that is distributed in the 
S and G2 phases of the cell cycle and plays an important 
role in the formation of the mitotic spindle [8, 9]. TPX2 
over-expression occurs in various malignant tumors, 
resulting in abnormal cell centrosome amplification [10], 
aneuploid cell formation, and malignant transformation 
[11]. However, no report concerning TPX2 expression 
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and its prognostic value in gastric carcinoma exists in 
the literature. In this study, we sought to investigate the 
expression of TPX2 and its associated prognostic signifi-
cance in gastric carcinoma.
Methods
Patients and tissue specimens
The ethics committee at the Binzhou Medical College 
Hospital approved this study, and all the patients pro-
vided written informed consent for the use of clinical 
specimens for medical research. For real-time polymer-
ase chain reaction (PCR) and Western blot analysis, 
twenty paired gastric carcinoma and adjacent normal 
tissues from Binzhou Medical College Hospital between 
April 2014 and July 2014 were collected. In addition, 106 
paraffin-embedded gastric carcinoma specimens were 
collected between February 2002 and December 2003 
for immunohistochemical (IHC) assays. The median age 
of the patients was 53 years (range 28–75 years), and the 
median tumor size was 5.6 cm (range 0.5–16 cm, one full 
stomach infiltration). All the patients were diagnosed 
with gastric adenocarcinoma. None of them received any 
type of neoadjuvant therapy, and all underwent curative 
surgery. Gastrectomy plus standard D2 lymphadenec-
tomy was performed by the same surgical team. After 
surgery, chemotherapy was administered to patients with 
advanced-stage disease, but none of the patients received 
radiation treatment. Tumor stage and differentiation 
grade were assessed according to the 7th Edition of the 
UICC/AJCC TNM Staging System. Both tumor and adja-
cent non-tumor tissues (the adjacent non-tumor tissue 
was defined as being located at least 5 cm from the tumor 
edge) were processed immediately after surgery. The ini-
tial event in the survival analysis was the surgical treat-
ment time of the patients, and the time of patient death 
was the end time; this interval was defined as the survival 
time of patients.
RT‑PCR analysis
Total RNA from human gastric carcinoma tissues and the 
adjacent normal gastric tissues was extracted using TRI-
zol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. The RNA was purified using 
RNeasy Micro columns (Qiagen, Valencia, CA), and 1 μg 
of RNA from each sample was used for cDNA synthesis 
primed with random hexamers. Quantitative real-time 
PCR was then performed using SYBR Green I (TaKaRa, 
Dalian, CHN) (Applied Biosystems Step-one TM Real-
Time PCR System). Each reaction was run in triplicate 
in three independent experiments. For PCR amplifica-
tion, TPX2-specific primers were used with denaturation 
at 95 °C for 10 min, followed by 35 denaturation cycles at 
95  °C for 20 s, primer annealing at 58  °C for 20 s, and a 
primer extension phase at 72 °C for 20 s. A final extension 
step at 72 °C for 5 min was performed before the reaction 
mixture was stored at 4 °C. The primer sequences were as 
follows: TPX2: sense 5′-ACCTTGCCCTACTAAGATT-3′, 
antisense 5′-AATGTGGCACAGGTTGAGC-3′; GAPDH: 
sense 5′-CTCCTCCTGTTCGACAGTCAG-C-3′, anti-
sense 5′-CCCAATACGACCAAATCCGTT-3′. Expres-
sion data were normalized to the geometric mean of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to 
control the variability in the expression levels. In all the 
cases, the validity of amplification was confirmed by the 
presence of a single peak in the melting temperature anal-
ysis and linear amplification with an increasing number of 
PCR cycles.
Western blot analysis
Fresh gastric carcinoma tissues and normal gastric tis-
sues were ground to a powder in liquid nitrogen and 
were lysed with sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) sample buffer. To detect 
TPX2 expression at the protein level, equal protein sam-
ples (30 μg) extracted from the tissues were separated on 
8  % SDS-polyacrylamide gels and transferred to polyvi-
nylidene fluoride (PVDF) membranes (Immobilon P; 
Millipore, Bedford, MA). The membranes were blocked 
with 5 % fat-free milk in Tris-buffered saline containing 
0.1  % Tween-20 (TBST) for 0.5  h at room temperature. 
The membranes were incubated with primary antibod-
ies against TPX2 (1:500; Proteintech, USA, 11741-1-AP) 
for 3  h at room temperature and then with horserad-
ish peroxidase-conjugated goat anti-rabbit IgG (Santa 
Cruz Biotechnology, SC-2004). Immunoreactive sig-
nals for mature TPX2 (100 kDa) were detected using an 
enhanced chemiluminescent substrate (SuperSignal West 
Pico Chemiluminescent Substrate; Pierce Chemical, 
Rockford, IL, USA). GAPDH (1:1000, Proteintech, USA) 
was used as a loading control.
Tissue microarray (TMA) preparation
A representative tissue area was first selected on a hema-
toxylin and eosin (HE)-stained slide for preparation of 
the TMA sections. Next, the selected area was punched 
out using a biopsy needle, and a 3-mm tissue core was 
transferred to a recipient block. Two tissue cores of gas-
tric tumor and an additional normal gastric tissue core 
were deposited in a paraffin block using a semi-auto-
mated tissue arrayer.
Immunohistochemistry
IHC staining was performed according to the manufac-
turer’s protocol. The TMA slides were baked for 1  h at 
65  °C, deparaffinized with xylene, and rehydrated using 
a graded ethanol series and distilled water. After the 
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sections were immersed twice in PBS, peroxidase block-
ing solution was added dropwise to block endogenous 
peroxidase activity, and the paraffin sections were incu-
bated at room temperature for 10  min. Non-immune 
bovine serum was added, and the samples were incu-
bated at room temperature for 10 min. The sections were 
incubated with TPX2 antibodies overnight at 4  °C. The 
paraffin sections were washed three times with PBS and 
then incubated with biotin-conjugated anti-rabbit sec-
ondary antibody at room temperature for 2  h, followed 
by incubation in streptavidin–biotin peroxidase solution 
at room temperature for 10 min and color development 
with 3,3′-diaminobenzidine (DAB).
The IHC scores were determined by the average 
score assigned by two pathologists. Immunoreactivi-
ties were scored by the intensity of staining (0 no stain-
ing; 1 weak =  light yellow; 2 moderate = yellow brown; 
3 strong = brown) and the percentage of stained cells (0 
no staining; 1, 0–10 %; 2, 11–30 %; 3, 31–70 %; 4, >71 %). 
By multiplication of both values, a final score ranging 
between 0 and 12 was obtained. TPX2 over-expression 
was defined as a final score greater than zero.
Statistical analysis
The TPX2 mRNA transcriptional levels in the tumor and 
matched non-tumor tissues were compared by the paired 
sample t test method. The TPX2 positivity rates in tumor 
and matched adjacent non-tumor tissues were compared 
using the Chi square test. Clinicopathological features of 
TPX2-positive patients and TPX2-negative patients were 
compared using the Chi square test for categorical vari-
ables and Student’s t test for continuous data. Overall sur-
vival (OS) was defined as the time from surgery until death. 
Patients who were alive and disease-free were censored at 
the date of the last follow-up. The Kaplan–Meier method 
was used to analyze the OS of patients, and comparisons 
were performed using the log-rank test. Cox’s proportional 
hazards model was used for multivariate analysis, and the 
adjusted hazard ratios (HRs) and their 95  % confidence 
intervals (CIs) were calculated. All the statistical analyses 
were conducted using the Statistical Software Package for 
the Social Sciences (SPSS Inc., Chicago, IL, USA). All the 
statistical tests were two-sided, and a p value less than 0.05 
was considered statistically significant.
Results
TPX2 is up‑regulated in gastric carcinoma
To determine whether TPX2 mRNA expression was dif-
ferent between gastric carcinoma and normal gastric 
samples, we first queried the Oncomine database (http://
www.oncomine.org). In the meta-analysis, TPX2 expres-
sion was significantly higher in the gastric carcinoma tis-
sues than in the corresponding normal tissues (median 
rank of 187.5, P value of 8.51E−8; Fig.  1). To confirm 
this result, we obtained twenty paired gastric carcinoma 
and adjacent normal tissues for real-time quantitative 
polymerase chain reaction (RT-PCR) analysis. As shown 
in Fig.  2, the expression level of TPX2 mRNA was sig-
nificantly higher in tumor tissues (P  =  0.002). Western 
blotting analysis revealed that TPX2 protein was dif-
ferentially increased in 17 of 20 primary human gastric 
carcinoma tissue specimens compared with the adjacent 
non-tumor tissues, indicating that TPX2 is up-regulated 
in gastric carcinoma (Fig. 3a; Additional file 1: Figure S1). 
However, in the remaining 3 paired tissues, the levels of 
TPX2 expression were similar, even lower, in tumor tis-
sues than in non-tumor tissues (Fig. 3a; No. 7, 12 and 15). 
Furthermore, these results were confirmed by immuno-
histochemistry. The TPX2 positivity rate was 66.98  % 
(71/106) in tumor tissues. In non-cancerous adjacent 
tissues, TPX2 protein staining was present in a few cells 
and was very weak (Figs. 3a, 4). TPX2 was predominantly 
present in the nucleus and cytoplasm of tumor cells 
(Fig. 5). These data demonstrated that TPX2 was signifi-
cantly increased in gastric carcinoma.
TPX2 is correlated with the clinicopathological features 
of gastric carcinoma
To obtain a better understanding of the potential roles 
of TPX2 in gastric carcinoma development and progres-
sion, we investigated the relationship between TPX2 
expression and other clinicopathological features in 
106 paraffin-embedded archived gastric cancer tissues, 
including 10 stage I tumors, 10 stage II tumors, 84 stage 
III tumors, and 2 stage IVa tumors. Among 106 samples, 
high TPX2 protein expression was detected in 71 sam-
ples (66.98 %), and weak or no staining was observed in 
35 tumor samples (33.02 %; Table 1). As shown in Fig. 3, 
TPX2 was highly expressed in gastric cancer tissues. By 
contrast, no signals or only weak signals were detected in 
adjacent non-cancerous tissues. The subcellular location 
of TPX2 was mainly in the nucleus and cytoplasm.
We further analyzed the correlation between TPX2 
expression and the clinicopathological characteristics 
of patients. As is summarized in Table 1, TPX2 expres-
sion was significantly associated with age (P = 0.001) and 
T stage (P =  0.003). However, there was no correlation 
between TPX2 expression and other clinical features, 
such as gender, N/M stage, and tumor size (Table 1).
Univariate and multivariate analyses of the prognosis 
of gastric carcinoma patients
Univariate and multivariate analyses were carried out 
using the Cox proportional hazards regression model 
to investigate the prognostic value of TPX2 expression 
(Table 2). Age, tumor size, N stage, clinical AJCC stage, 
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and high TPX2 expression predicted a poor prognosis 
in the univariate analysis (P  =  0.001, 0.001, 0.000, 0.03 
and 0.001, respectively). In the multivariate analysis of 
the prognostic factors, we confirmed that high TPX2 
expression was an independent prognostic factor (95  % 
CI 2.626–7.198; P =  0.001), and age, tumor size, and N 
stage were also independent and significant prognostic 
factors for OS (P = 0.046, 0.005 and 0.000).
Expression of TPX2 in gastric carcinoma patients correlates 
with a worse overall survival
After a median follow-up of 101  months (range 
1–118 months), 89 (83.1 %) patients died. The estimated 
5-year OS was 21  % (95  % CI 17.122–24.878). Survival 
analysis showed a clear negative correlation between the 
TPX2 protein expression level and OS of patients with 
gastric cancer (P = 0.001; Fig. 5). Patients with negative 
TPX2 expression had an estimated 5-year OS rate of 57 % 
(95 % CI 43.091–70.909), whereas patients with positive 
TPX2 expression had a 5-year OS rate of 14 % (95 % CI 
10.333–17.667, P = 0.001; Fig. 5). These results indicated 
that TPX2 expression may be an independent prognostic 
marker for OS in gastric carcinoma patients.
Discussion
Gastric carcinoma is one of the main cancer-related 
causes of death worldwide [1, 12]. The curative treat-
ment of gastric carcinoma consists of tumor resection 
Fig. 1 TPX2 expression is up-regulated in human gastric carcinomas in the Oncomine database. Oncomine heat map of TPX2 gene expression in 
clinical gastric carcinoma samples compared with normal gastric tissues (http://www.oncomine.org). In the meta-analysis, TPX2 expression was 
significantly higher than that in the corresponding normal tissues in gastric carcinoma, with a median rank of 187.5 and a p value of 8.51E−8
Fig. 2 Overexpression of TPX2 mRNA in gastric carcinoma tissues. 
Expression levels of TPX2 mRNA in 20 paired gastric carcinoma tissues 
according to real-time PCR. The results show that the expression 
levels of TPX2 mRNA were significantly higher in tumor tissues than 
in the paired normal tissues (P = 0.002). Normal, matched adjacent 
non-tumor gastric tissues. Tumor, gastric carcinoma tissues. GAPDH 
was used as the internal control
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and lymphadenectomy [13]. However, surgical treat-
ment alone is associated with high recurrence rates 
[14]. Adjuvant treatment strategies have demonstrated 
controversial results [15]. Despite improvement in early 
detection and treatments, the outcome of advanced gas-
tric carcinoma remains unsatisfactory due to the poor 
understanding of the intricate pathogenesis of gastric 
carcinoma. Gastric carcinoma is a multifactorial and 
multistep disease [16] that involves activation of onco-
genes and inactivation of tumor suppressor genes [17]. 
A multimodal approach has been demonstrated to sig-
nificantly increase OS, and it can be offered in the form 
of perioperative chemotherapy, adjuvant chemora-
diotherapy, or adjuvant chemotherapy [18]. Recently, 
numerous studies have investigated the molecular basis 
of gastric carcinoma [19], involving the alteration of 
pathogenesis, as well as invasion and metastasis [20, 21]. 
With the development of modern technologies, various 
novel biomarkers have been identified that appear to pos-
sess diagnostic and prognostic value [22, 23]. Identifying 
useful biomarkers for the early diagnosis and prognosis 
of gastric carcinoma is an urgent need.
TPX2 has been identified as a mitotic regulator 
involved in the formation of the mitotic spindle [24]. 
This protein, as well as its partner, Aurora-A, is fre-
quently overexpressed in many tumor types [25], and its 
deregulation may participate not only in chromosomal 
numerical aberrations but also in other forms of genomic 
instability in cancer cells [26]. Overexpressed in cancers, 
TPX2 is regarded as a novel candidate target for the diag-
nosis and prognosis of malignancies [11]. During inter-
phase, TPX2 resides preferentially in the nucleus, where 
Fig. 3 Overexpression of TPX2 protein in human gastric carcinoma tissues. a Western blot analyses of TPX2 protein expression in twenty matched 
pairs of gastric carcinoma (T) and adjacent noncancerous tissues (ANT). GAPDH was used as the loading control. b Immunohistochemical assay 
of TPX2 protein expression in six pairs of matched gastric carcinoma tissues. T gastric carcinoma tissues, ANT matched adjacent non-tumor gastric 
tissues (×400)
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its function has remained elusive until recently [11]. The 
latest finding that TPX2 plays a role in amplification of 
the DNA damage response [27], combined with the char-
acterization of TPX2 knockout mice [26], provides a new 
perspective in understanding the signaling roles of TPX2 
as they relate to cancer therapies. Additionally, it was 
found that the expression of TPX2 was associated with 
tumor grade, stage, lymph node metastasis, and tumor 
size pathological type [28].
Based on previous studies, we investigated the expres-
sion of TPX2 in gastric carcinoma and its prognostic value 
in predicting OS following curative resection in the pre-
sent study. Our results clearly showed that TPX2 was up-
regulated at both the mRNA and protein levels in twenty 
gastric carcinoma tissues compared with matched non-
tumor gastric tissues. In addition, IHC analysis showed 
that TPX2 was overexpressed in 78 of 106 (73.58 %) gas-
tric carcinoma specimens. The difference in the expres-
sion of TPX2 between gastric carcinoma and non-tumor 
Fig. 4 Expression analysis of TPX2 protein by immunohistochemistry. TPX2 expression was mainly localized in the nucleus and cytoplasm of tumor 
cells. a Staining of TPX2 in normal gastric tissues (×400). b Low expression of TPX2 in gastric carcinoma tissues (stage II) (×400). c Medium expres-
sion of TPX2 in gastric carcinoma tissues (stage III) (×400). d Higher expression of TPX2 in gastric carcinoma tissues (stage IV) (×400)
Fig. 5 Correlation of TPX2 expression with patient overall survival in 
gastric carcinoma. Kaplan–Meier curves with univariate analysis (log-
rank). OS rates for cases with high TPX2 expression versus those with 
low TPX2 expression levels in all patients. High TPX2 expression was 
correlated with an unfavorable prognosis (P = 0.001)
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tissues indicates that TPX2 may be a key regulator in tum-
origenesis and the prognosis of gastric carcinoma.
We further analyzed the relationship between the 
expression of TPX2 and the clinical characteristics of 
patients with gastric carcinoma. There was a significant 
correlation of TPX2 expression with age (P = 0.001) and 
T stage (P = 0.003). However, there was no correlation of 
TPX2 expression with other clinical features, such as gen-
der, N/M stage, and tumor size, in contrast to the findings 
of other studies. This discrepancy may be due to the dif-
ferences in ethnicity and sample size between the studies.
Multivariate analysis revealed that TPX2 expression, 
age, tumor size, and N stage may be independent prog-
nostic indicators of OS in gastric carcinoma patients. 
This finding indicates the possibility of using high expres-
sion levels of TPX2 as a predictor of prognosis and 
survival.
However, sex, AJCC tumor stage, distant metastasis, 
and infiltration were not independent prognostic indica-
tors of OS in gastric carcinoma patients. It is unclear why 
AJCC clinical stage was not found to be an independent 
prognostic indicator of OS in gastric carcinoma patients. 
A possible reason is the small sample size in this study. 
Thus, we plan to collect more patients at different clini-
cal centers and perform an in-depth investigation of the 
mechanism of TPX2 action in our future research.
To our knowledge, this is the first report on TPX2 in 
gastric carcinoma, which was found to be an independ-
ent predictor of OS in gastric carcinoma patients. Fur-
ther studies are warranted to elucidate the molecular 
mechanism of TPX2 in the development and progression 
of gastric carcinoma.
Table 1 Correlation of TPX2 expression with clinicopatho-
logic features
The results of immune-histochemical score were determined by the average 
score that given by two pathologists, immune-reactivities were scored by the 
intensity of staining (0, no staining; 1 weak = light yellow; 2 moderate = yellow 
brown; 3 strong = brown) and the percentage of stained cells (0 no staining; 1, 
0–10 %; 2, 11–30 %; 3, 31–70 %; 4, >71 %). By multiplication of both values, a 
final score ranging between 0 and 12 was obtained. TPX2 over-expression was 











 Male 67 (63.2 %) 22 (32.8 %) 45 (67.2 %) 0.958
 Female 39 (36.8 %) 13 (33.3 %) 26 (66.7 %)
Age (years)
 ≥60 46 (43.4 %) 7 (15.2 %) 39 (84.8 %) 0.001
 <60 60 (56.6 %) 28 (46.7 %) 32 (53.3 %)
T stage
 1 10 (9.4 %) 8 (80 %) 2 (20 %) 0.003
 2 10 (9.4 %) 4 (40 %) 6 (60 %)
 3 84 (79.2 %) 22 (26.2 %) 62 (73.8 %)
 4a 2 (1.9 %) 1 (50 %) 1 (50 %)
N stage
 0 21 (19.8 %) 10 (47.6 %) 11 (35.2 %) 0.120
 1 38 (35.8 %) 14 (36.8 %) 24 (63.2 %)
 3 47 (44.3 %) 11 (6.3 %) 36 (3.6 %)
M stage
 0 99 (93.4 %) 34 (34.3 %) 65 (65.7 %) 0.421
 1 7 (6.6 %) 1 (14.3 %) 6 (85.7 %)
TNM stage
 I 13 (12.3 %) 5 (38.5 %) 8 (61.5 %) 0.144
 II 17 (16.0 %) 8 (47.1 %) 9 (52.9 %)
 III 69 (65.1 %) 22 (31.9 %) 47 (68.1 %)
 IV 7 (6.3 %) 0 (0 %) 7 (100 %)
Tumor size (cm)
 ≥5 74 (69.8 %) 24 (32.4 %) 50 (67.6 %) 1.000
 <5 32 (30.2 %) 11 (34.4 %) 21 (65.6 %)
Table 2 Cox-regression analysis of  various prognostic 
parameters in patients for all patients
Factor Univariate Multivariate
HR (95 % CI) P value HR (95 % CI) P value
Sex
 Male Reference
 Female 0.883 (0.581–1.340) 0.558 – –
Age
 ≥60 Reference
 <60 2.077 (1.375–3.139) 0.001 1.561 (1.009–2.417) 0.046
Tumor size (cm)
 <5 Reference





 Positive 3.703 (2.303–5.956) 0.001 4.708 (2.800–7.917) 0
AJCC tumor stage
 I Reference
 II 1.971 (0.840–4.624) 0.119 – –
 III 2.268 (1.081–4.756) 0.030 – –
 IV 2.666 (0.963–7.382) 0.059 – –
N stage
 0 Reference 0
 1 4.022 (1.955–8.274) 0.000 3.122 (1.474–6.611) 0.003
 3 7.015 (3.421–
14.386)
0.000 5.858 (2.731–12.566) 0
Distant metastasis
 No Reference
 Yes 0.855 (0.346–2.110) 0.733 – –
Infiltration
 No Reference
 Yes 2.023 (0.639–6.402) 0.231 – –
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